| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | Hartz County TX CULTURAL | Apr 10, 2026 | |
| Sell | Heron Therapeutics, Inc. | Mar 31, 2021 |
This page tracks congressional stock trading activity in Heron Therapeutics, Inc. (HRTX) in the Healthcare sector. Disclosed Capitol has indexed 2 disclosed congressional trades involving HRTX. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of May 2026 — Disclosed Capitol has tracked 2 disclosed congressional trades in Heron Therapeutics, Inc. (HRTX) — 1 sells with no recorded buys — led by Diana Harshbarger (R).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Apr 10, 2026 | Diana Harshbarger | R | Buy | $15,001 - $50,000 |
| Mar 31, 2021 | Ashley Hinson Arenholz | R | Sale | $1,001 - $15,000 |
Across the 2 disclosed congressional trades in Heron Therapeutics, Inc. (HRTX), members of Congress have reported 0 buys and 1 sell. The average 30-day alpha vs. the S&P 500 is -4.49%.
As of August 2026, corporate insiders at Heron Therapeutics, Inc. have filed 20 SEC Form 4 transactions in HRTX over the past 12 months.
| Date | Insider | Action | Value |
|---|---|---|---|
| 2026-08-06 | Hensley Mark Earl — Chief Operating Officer | Option Exercise | — |
| 2026-08-06 | Hensley Mark Earl — Chief Operating Officer | Tax Withholding | $4K |
| 2026-07-31 | Hensley Mark Earl — Chief Operating Officer | Option Exercise | — |
| 2026-07-31 | Forbes William P — EVP, Chief Development Officer | Option Exercise | — |
| 2026-07-31 | Forbes William P — EVP, Chief Development Officer | Tax Withholding | $2K |
| 2026-07-31 | Duarte Ira — EVP, Chief Financial Officer | Option Exercise | — |
| 2026-07-31 | Duarte Ira — EVP, Chief Financial Officer | Tax Withholding | $2K |
| 2026-07-31 | Collard Craig A — Chief Executive Officer | Option Exercise | — |
| 2026-07-30 | Forbes William P — EVP, Chief Development Officer | Option Exercise | — |
| 2026-07-30 | Forbes William P — EVP, Chief Development Officer | Tax Withholding | $2K |
Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.
For fiscal year 2025, Heron Therapeutics, Inc. reported revenue of $154.9M and net income of -$20.2M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $72.4M, net income -$13.6M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.